amine image Erlotinib Structural Formulae.png width 250 image2 Erlotinib 1m17 3D balls.png CASNo Ref ... US Rx only legal status routes of administration Oral licence EU Tarceva licence US ErlotinibErlotinib ... and OSI Pharmaceuticals and elsewhere by Hoffmann La Roche Roche . Mechanism Erlotinib is an EGFR inhibitor . The drug follows Iressa gefitinib , which was the first drug of this type. Erlotinib specifically ... is not possible and the signal is stopped. Development Erlotinib has shown a survival benefit ... Administration FDA approved the use of erlotinib in combination with gemcitabine for treatment of locally ... to respond to erlotinib and other tyrosine kinase inhibitor s. Beyond smoking status, responses ... KRAS negative. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity .... The study suggests that erlotinib may be used for treatment of JAK2V617F positive PV and other ... X, Zhao Z title Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth ... preview ingredient index.php?query erlotinib ref In India, generic pharmaceutical firm Cipla is battling ... a final approval to Cipla to manufacture and sell its generic version of Erlotinib in India. ref ... firm Natco is also seeking to manufacture the generic version of Erlotinib in India but sell it to patients ... and Survival With Erlotinib in Patients With Non Small Cell Lung Cancer journal Journal of Clinical ..., ingrown hairs , such as eyelashes It has also been suggested that erlotinib can cause hearing loss ... and Drug Administration issued a warning on erlotinib. The FDA reported serious gastrointestinal ... by Genentech and OSI Pharmaceuticals , some people prescribed erlotinib have developed serious ... of erlotinib resistant tumors harboring the T790M mutation, because together they efficiently depleted ... against T790M EGFR mediated erlotinib resistant lung cancer, Br J Cancer. 2008 September 16 ... blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression ... more details
chembox ImageFile Entinostat.png ImageSize 200px IUPACName Pyridin 3 ylmethyl N nowiki nowiki 4 2 aminophenyl carbamoyl phenyl methyl carbamate OtherNames SNDX 275 MS 275 Section1 Chembox Identifiers CASNo 209783 80 2 PubChem 4261 KEGG D09338 SMILES C1 CC C C C1 N NC O C2 CC C C C2 CNC O OCC3 CN CC C3 Section2 Chembox Properties Formula C sub 21 sub H sub 20 sub N sub 4 sub O sub 3 sub MolarMass 376.4085 Appearance Density MeltingPt BoilingPt Solubility Section3 Chembox Hazards MainHazards FlashPt Autoignition Entinostat , also known as SNDX 275 and MS 275 , is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. ref http www.asco.org ASCOv2 Meetings Abstracts?&vmview abst detail view&confID 55&abstractID 31482 Phase I trial of 5 azacitidine 5AC and SNDX 275 in advanced lung cancer NSCLC ref Entinostat inhibits class I HDAC1 and HDAC3 with IC50 IC sub 50 sub of 0.51 M and 1.7 M, respectively. ref http www.freepatentsonline.com y2009 0263353.html Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles ref Clinical trials There is an ongoing phase II trial studying the effect of entinostat on Hodgkin s lymphoma . ref http clinicaltrials.gov ct2 show NCT00866333 A Phase 2 Multi Center Study of Entinostat SNDX 275 in Patient With Relapsed or Refractory Hodgkin s Lymphoma ref It is in other phase II trials for advanced breast cancer in combination with aromatase inhibitor s ref http clinicaltrials.gov ct2 show NCT00828854 A Phase 2, Multicenter Study of the Effect of the Addition of SNDX 275 to Continued Aromatase Inhibitor AI Therapy in Postmenopausal Women With ER Breast Cancer Whose Disease is Progressing ref and for metastatic lung cancer in combination with erlotinib ref http clinicaltrials.gov ct2 show NCT00750698 A Phase 2 Exploratory Study of Erlotinib and SNDX 275 in Patients With Non small Cell Lung Carcinoma Who Are Progressing on Erlotinib ref . References reflist pharma stub Category Pyridin ... more details
A Catalytic receptor is an integral membrane protein possessing both Enzyme enzymatic catalysis catalytic and Receptor biochemistry receptor functions. ref name pmid17279064 cite journal author Alexander SP, Mathie A, Peters JA title Catalytic receptors journal Br. J. Pharmacol. volume 150 Suppl 1 issue pages S122 7 year 2007 month February pmid 17279064 pmc 2013840 doi 10.1038 sj.bjp.0707205 url issn ref The following is a list of the five major families of catalytic receptors class wikitable Family Member Gene Catalytic activity Endogenous Ligands Synthetic Ligands align center rowspan 4 align center Erb ref name ErbB family cite journal author Alexander SP, Mathie A, Peters JA title Catalytic receptors ErbB family journal Br. J. Pharmacol. volume 150 Suppl 1 issue pages S146 year 2007 month February doi 10.1038 sj.bjp.0706476 url issn ref ErbB1 epidermal growth factor receptor Gene EGFR tyrosine kinase EC number 2.7.10.1 Epidermal growth factor , amphiregulin , betacellulin , epigen , epiregulin , Heparin binding EGF like growth factor HB EGF , TGF alpha TGFa GW583340, gefitinib , erlotinib , tyrphostins AG879 and AG1478 align center HER2 neu ErbB2 Gene ERBB2 align center ERBB3 ErbB3 Gene ERBB3 Neuregulin 1 NRG 1 , NRG2 NRG 2 GW583340, gefitinib, erlotinib, tyrphostins AG879 and AG1478 align center Her 4 ErbB4 Gene ERBB4 Betacellulin, epiregulin, HB EGF, NRG 1, NRG 2, NRG 3, NRG 4 GW583340, gefitinib, erlotinib, tyrphostins AG879 and AG1478 align center rowspan 4 align center GDNF glial cell derived neurotrophic factor ref name GDNF family cite journal author Alexander SP, Mathie A, Peters JA title Catalytic receptors GDNF family journal Br. J. Pharmacol. volume 150 Suppl 1 issue pages S147 year 2007 month February doi 10.1038 sj.bjp.0706477 url issn ref GFRA1 GFRa1 Gene GFRa1 GDNF neurturin artemin align center GFRA2 gene GFRa2 Gene GFRa2 Neurturin GDNF align center GFRA3 GFRa3 Gene GFRa3 Artemin align center GFRA4 GFRa4 Gene GFRa4 Persephin align center rowspan ... more details
Distinguish Cervical ectropion Infobox disease Name Ectropion ICD10 ICD10 H 02 1 h 00 , ICD10 Q 10 1 q 10 ICD9 ICD9 374.1 ICDO Image Caption OMIM OMIM mult MedlinePlus 001007 eMedicineSubj oph eMedicineTopic 211 DiseasesDB 4108 Ectropion is a medical condition in which the lower eyelid turns outwards. It is one of the notable aspects of newborns exhibiting congenital Harlequin type ichthyosis , but ectropion can occur due to any weakening of tissue of the lower eyelid. The condition can be repaired surgery surgically . Ectropion is also found in dog s as a genetic disorder in certain breeds. Causes Congenital Aging Scarring Mechanical Allergic Facial nerve palsy Anti cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR the epidermal growth factor receptor . Ectropion in dogs Image Ectropion.JPG thumb Ectropion in a Cocker Spaniel Ectropion in dogs usually involves the lower eyelid. Often the condition has no symptoms, but tearing and conjunctivitis may be seen. Breeds associated with ectropion include the Cocker Spaniel , the St. Bernard dog Saint Bernard , the Bloodhound , and the Basset Hound . ref name Gelatt 1999 cite book author Gelatt, Kirk N. ed. title Veterinary Ophthalmology edition 3rd ed. publisher Lippincott, Williams & Wilkins year 1999 isbn 0 683 30076 8 ref It can also result from Physical trauma trauma or nerve damage. Treatment surgery is only recommended if there is chronic conjunctivitis or if there is cornea l damage. A small part of the affected lid is removed and then the lid is sewn back together. See also Cervical erosion Cervical ectropion Entropion List of eye diseases and disorders References references External links GPnotebook 584056883 Eye pathology Congenital malformations and deformations of eye, ear, face and neck Category Dog diseases Category Disorders of eyelid, lacrimal system and orbit Category Congenital disorders of eye, ear, face and neck de Ektropium es Ectropi n fa fr E ... more details
2992 Monotherapy in Non small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib ref Fall 2010 ... by first generation TKIs like erlotinib or gefitinib , but also against those not sensitive to these standard ... more details
. Erlotinib marketed as Tarceva . Erlotinib inhibits epidermal growth factor receptor , ref ... pmc 2637898 ref and works through a similar mechanism as gefitinib. Erlotinib has been shown to increase ..., erlotinib has replaced gefitinib in this setting. Bortezomib Velcade is an apoptosis inducing ... more details
Refimprove date November 2008 Infobox Company company name Nanjing Ange Pharmaceutical Co. br company logo foundation 2003 company slogan Quality Technology and Service Foster Healthy Life location Nanjing, Jiangsu Province , PRC industry Pharmaceuticals , br Healthcare products Antineoplastic medicine , br pharmaceutical intermediates num employees 35 2007 num associates 8 homepage http www.angepharm.com template gsjja en.htm www.angepharm.com Nanjing Ange Pharmaceutical Co., Ltd. zh s t p N n j ng n g y y o hu g ng y u xi n g ng s is a pharmaceutical company in Nanjing , in the People s Republic of China , specializing in the development of New Drug s the drugs that previously have not been marketed in China, i.e., New Chemical Entities for China s FDA as well as the research, development, production and trade of chemical API s and pharmaceutical intermediate s. Company Profile Ange was founded in 2003, and is now a leading company in the Chinese pharmaceutical industry . With almost every major university in Nanjing Ange has established cooperative relationships and laboratories, including China Pharmaceutical University , China s first independent school of pharmacy and one of the few institutes with complete pharmaceutical fields ref China Pharmaceutical University ref . Main Products Ange s main products are Antineoplastic medicines, which include Sunitinib Lapatinib Nilotinib Dasatinib Gefitinib Erlotinib Imatinib Canertinib It also produces relative pharmaceutical intermediates. Recent Projects In the past 2 years, Ange has been working with Abbott Laboratories Ltd. and Simcere Pharmaceutical Group , etc. ref cite web url http www.angepharm.com template gsjja en.htm title About Us ref References reflist External links http www.angepharm.com template gsjja en.htm Ange Official Web Site en Pharmaceutical companies of China Category Biotechnology companies Category Pharmaceutical companies of China Category Companies b ... more details
List of drugs E Eq Es eq Equagesic Equanil Equipin er erb ert erbulozole International Nonproprietary Name INN Ercatab erdosteine International Nonproprietary Name INN Ergamisol Ergamisol Janssen Research Foundation ergocalciferol International Nonproprietary Name INN Ergoloid Mesylates Ergomar ergometrine International Nonproprietary Name INN Ergostat ergotamine International Nonproprietary Name INN eribaxaban United States Adopted Name USAN , International Nonproprietary Name INN eribulin International Nonproprietary Name INN investigational drug ericolol International Nonproprietary Name INN eritoran tetrasodium United States Adopted Name USAN eritrityl tetranitrate International Nonproprietary Name INN erizepine International Nonproprietary Name INN erlizumab International Nonproprietary Name INN erlotinib hydrochloride United States Adopted Name USAN ertapenem sodium United States Adopted Name USAN ertiprotafib United States Adopted Name USAN ertumaxomab International Nonproprietary Name INN erocainide International Nonproprietary Name INN Errin ersentilide International Nonproprietary Name INN ersofermin International Nonproprietary Name INN Ertaczo ertumaxomab International Nonproprietary Name INN ery Ery Tab Eryc Erycette Eryderm Erygel Erymax Erypar Eryped Erythra Derm Erythro Statin Erythrocin erythromycin acistrate International Nonproprietary Name INN erythromycin stinoprate International Nonproprietary Name INN erythromycin International Nonproprietary Name INN Eryzole es esa esr esafloxacin International Nonproprietary Name INN esaprazole International Nonproprietary Name INN Esclim esculamine International Nonproprietary Name INN eseridine International Nonproprietary Name INN esflurbiprofen International Nonproprietary Name INN Esgic Esidrix Esimil Eskalith eslicarbazepine United States Adopted Name USAN esmirtazapine United States Adopted Name USAN , International Nonproprietary Name INN esmolol International Nonproprietary Name INN esomeprazole Int ... more details
Infobox Disease Name PAGENAME Image Drug eruptions.jpg Caption Examples of drug eruptions. A Bullous dermatitis caused by sulfathiazole B Fixed drug eruption caused by phenolphtalein C Bullous erythema multiforme D Diffuse photosensitivity reaction . DiseasesDB ICD10 ICD10 L 27 0 l 20 , ICD10 L 27 1 l 20 ICD9 ICD9 692.3 , ICD9 782.1 ICDO OMIM MedlinePlus eMedicineSubj derm eMedicineTopic 104 MeshID D003875 In medicine , a drug eruption is an adverse drug reaction of the Human skin skin . Most drug induced cutaneous reactions are mild and disappear when the offending drug is withdrawn. ref name pmid7762478 cite journal author Manders SM title Serious and life threatening drug eruptions journal Am Fam Physician volume 51 issue 8 pages 1865 72 year 1995 month June pmid 7762478 doi url ref Drugs can also cause hair disease hair and nail disease nail changes, affect the mucous membranes , or cause itching without outward skin changes. ref name pmid17973540 Diagnosis Drug eruptions are diagnosed mainly from the medical history and clinical examination . However, they can mimic a wide range of other conditions, thus delaying diagnosis for example, in drug induced lupus erythematosus , or the acne like rash caused by erlotinib . A skin biopsy , blood test s or immunology immunological tests can also be useful. If the causative agent can not be withdrawn, the symptoms should be relieved as much as possible. It is estimated that 2 3 percent of hospitalised patients are affected by a drug eruption, and that serious drug eruptions occur in around 1 in 1000 patients. ref name pmid7794310 cite journal author Roujeau JC, Stern RS title Severe adverse cutaneous reactions to drugs journal N. Engl. J. Med. volume 331 issue 19 pages 1272 85 year 1994 month November pmid 7794310 doi 10.1056 NEJM199411103311906 url http content.nejm.org cgi pmidlookup?view short&pmid 7794310&promo ONFLNS19 ref Classification The drug eruption can be an expected adverse effect or an unexpected effect idi ... more details
12 month March year 2007 pmid 17551677 doi 10.1007 s11739 007 0002 5 pmc 2780603 ref Erlotinib Tarceva ... growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non small cell ... M, Sridhara R, et al. title Approval summary for erlotinib for treatment of patients with locally ... more details
therapy used in squamous cell cancers of the head and neck include cetuximab , bevacizumab , erlotinib ... growth factor VEGF , were recruiting patients As of March 2007 . Erlotinib is an oral EGFR inhibitor ... of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent ... of erlotinib is otherwise lacking to this point. A clinical trial evaluating the use of erlotinib in metastatic head and neck cancer is recruiting patients as of March, 2007. Reovirus ... more details
genetic markers, Erlotinib may be an additional treatment option for this condition. ref cite journal author Li Z, Xu M, Xing S, Ho W, Ishii T, Li Q, Fu X, Zhao Z title Erlotinib effectively inhibits ... more details
pancreatic cancer, the US FDA in 2005 licensed the use of erlotinib Tarceva in combination with gemcitabine ... erlotinib to gemcitabine placebo, and demonstrated improved survival rates, improved tumor ... 20pancreatic 22 title Tarceva erlotinib Tablets. NDA 21 743, S003. Supplemental NDA Pancreatic Cancer ... more details
Encyclopedia
top
